Jonathan Ross Goodman Buys 19,200 Shares of Knight Therapeutics Inc. (TSE:GUD) Stock

Knight Therapeutics Inc. (TSE:GUDGet Rating) Director Jonathan Ross Goodman acquired 19,200 shares of Knight Therapeutics stock in a transaction on Friday, December 3rd. The stock was purchased at an average price of C$5.21 per share, with a total value of C$100,032.00.

Knight Therapeutics stock opened at C$5.35 on Friday. The company has a debt-to-equity ratio of 4.86, a quick ratio of 2.09 and a current ratio of 2.90. The firm has a market capitalization of C$626.09 million and a price-to-earnings ratio of 42.46. Knight Therapeutics Inc. has a fifty-two week low of C$5.01 and a fifty-two week high of C$5.74. The stock’s fifty day moving average is C$5.42 and its two-hundred day moving average is C$5.34.

Knight Therapeutics (TSE:GUDGet Rating) last posted its quarterly earnings data on Thursday, March 24th. The company reported C($0.08) EPS for the quarter. The company had revenue of C$58.27 million during the quarter, compared to analyst estimates of C$61.00 million. As a group, sell-side analysts forecast that Knight Therapeutics Inc. will post 0.06 EPS for the current fiscal year.

GUD has been the subject of a number of research reports. National Bank Financial reduced their price objective on Knight Therapeutics from C$8.00 to C$7.50 and set an “outperform” rating for the company in a research note on Friday, March 25th. Raymond James set a C$7.50 price target on Knight Therapeutics and gave the stock an “outperform” rating in a research note on Friday, April 1st. Stifel Nicolaus cut Knight Therapeutics to a “hold” rating and set a C$5.30 price target for the company. in a research note on Thursday, March 24th. Canaccord Genuity Group cut their price target on Knight Therapeutics from C$8.00 to C$7.00 in a research note on Friday, March 25th. Finally, Bloom Burton reaffirmed a “buy” rating and set a C$6.70 price objective on shares of Knight Therapeutics in a report on Monday, March 28th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of C$7.00.

Knight Therapeutics Company Profile (Get Rating)

Knight Therapeutics Inc, a specialty pharmaceutical company, develops, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices in Canada and internationally. It offers Bijuva for the treatment of moderate to severe vasomotor symptoms associated with menopause in women with intact uterus; IMVEXXY to treat postmenopausal moderate to severe dyspareunia; IBSRELA for the treatment of irritable bowel syndrome with constipation in adults; TRELSTAR to treat advanced prostate cancer and for pain associated with endometriosis; ILUVIEN for the treatment of vision loss due to diabetic macular oedema; and NERLYNX to treat early-stage breast cancer.

Recommended Stories

Insider Buying and Selling by Quarter for Knight Therapeutics (TSE:GUD)

Receive News & Ratings for Knight Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Knight Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.